NCT06915025Phase 3Recruiting

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Study sponsor: Imunon

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2032-10-31Estimated

Enrollment · participants500Estimated

Source updated2026-09-15Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma

Treatments or interventions studied

IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)DrugAlso known as GEN-1
PaclitaxelDrug
CarboplatinDrug
OlaparibDrugAlso known as Lynparza
NiraparibDrugAlso known as Zejula

Primary outcomes · main study measures

measure: Overall Survival; description: Overall Survival is defined as the time (in months) from the date of randomization to the date of death by any cause.; timeFrame: 48 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history